
AMGEN INC lowered disease activity scores by 5.6 points in a late-stage trial for its experimental Sjogren's syndrome drug, dazodalibep. The treatment outperformed a placebo group reduction of 3.8 points over a 48-week period. The results follow initial data released by the company in September.






